An investigation for investors in Acorda Therapeutics Inc (NASDAQ:ACOR) shares over potential securities laws violations by Acorda Therapeutics was announced.
San Diego, CA -- (SBWIRE) -- 09/18/2017 -- An investigation on behalf of investors of Acorda Therapeutics Inc shares over potential securities laws violations was announced.
Investors who purchased shares of Acorda Therapeutics Inc (NASDAQ:ACOR), have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm focuses on whether a series of statements by Acorda Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On August 29, 2017, Acorda Therapeutics Inc disclosed that it had received a Refusal to File ("RTF") letter from the U.S. Food and Drug Administration ("FDA") regarding the new drug application ("NDA") it had submitted in June for Inbrija, a potential treatment for Parkinson's disease. Acorda Therapeutics Inc stated, "FDA specified two reasons for the RTF: first, the date when the manufacturing site would be ready for inspection, and, second, a question regarding the submission of the drug master production record."
Those who purchased shares of Acorda Therapeutics Inc (NASDAQ:ACOR) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego